Conversion of Seddon III Nerve Injury to Seddon I/II Nerve Injury
NCT ID: NCT03236064
Last Updated: 2021-01-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
10 participants
INTERVENTIONAL
2016-05-31
2024-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Optimization of Peripheral Nerve Reconstruction: A Non-inferiority Trial
NCT01573650
Regenerative Peripheral Nerve Interfaces to Treat Painful Digit and Hand Neuromas After Amputation
NCT05008185
The Peripheral Mobilized Mononuclear Cell-based Therapy in Patient With Diabetic Neuropathy
NCT02315235
Sensory Reeducation in Peripheral Nerve Injuries of Hand
NCT01215760
Targeted Reinnervation as a Means to Treat Neuromas Associated With Major Limb Amputation
NCT02205385
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The first study proposed will be PEG fusion in digital nerve lacerations. Two goals will be demonstrated; improved innervation density and improved innervation threshold compared to traditional repair, and complication rate similar or less than traditional repair. This will demonstrate the safety and efficacy of the procedure.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nerve injury to palm and fingers
Adult patients with acute clean nerve transections of the higher arm injuries in the forearm, wrist, palm and digits of the hand will be recruited
Polyethylene Glycols
Demonstrate more rapid and increased return of function by PEG-fusion compared to best current nerve repair techniques
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Polyethylene Glycols
Demonstrate more rapid and increased return of function by PEG-fusion compared to best current nerve repair techniques
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
16 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Neuraptive Therapeutics Inc.
INDUSTRY
WellSpan Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Richard C Trevino, MD
Role: PRINCIPAL_INVESTIGATOR
WellSpan York Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
WellSpanYork Hospital
York, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
E
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
696230-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.